Phase II Study of Stereotactic Ablative Radiation Therapy for Adults With 6 to 10 Metastatic Cancer Sites

What this Trial Is About

Researchers are evaluating stereotactic ablative radiation therapy SABR for patients with metastatic cancer who have 6 to 10 metastatic sites in bones and internal organs. This study focuses on patients with persistent or progressive metastatic tumors who continue their current drug therapy. The goal is to assess the safety and effectiveness of radiation treatment for these patients, as current radiation approaches have shown benefits for those with fewer metastases, but less is known for patients with more than five metastatic sites. The study uses stereotactic radiation therapy applied to each metastatic site in ablative doses. Treatment planning involves advanced imaging techniques like three- or four-dimensional computed tomography, fixation devices, and contouring of targets and organs at risk. Various radiation doses and schedules are tailored depending on tumor location, such as lungs, brain, liver, bones, and adrenal glands. Radiation sessions use a linear accelerator with real-time visual control and special breathing techniques when needed. The radiation course lasts between 1 to 8 working days following up to 3 days of preparation. Participants undergo a thorough pre-treatment examination, followed by detailed radiation therapy. After treatment, they are monitored at 3, 6, 9, and 12 months, then every 6 months for up to 5 years. Researchers collect and analyze data on treatment safety and effectiveness, including progression-free survival, local control, overall survival, and timing of changes in chemotherapy. Participants continue their regular cancer care and provide informed consent to join the study.

OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites